Neumous
Seoul, South KoreaSee on the mapFounded 2022
- Focused ultrasound
Neumous is a medical technology company developing a non-invasive focused ultrasound platform for treating neurological disorders. Its technology is designed to temporarily open the blood-brain barrier for targeted delivery of therapeutics and to support precise neuromodulation, with clinical development underway for brain diseases.
- RaisedTotal raised
- $7M
- Investors
- 10
- Founded
- 2022
- Employees
- 11–50
reccy insights
Neumous, founded in 2022 and based in Seoul, is developing a therapeutic ultrasound platform intended to temporarily open the blood-brain barrier and support targeted delivery of treatments to the brain. Its stated approach combines focused ultrasound with systemically administered microbubbles, neuronavigation for targeting, and real-time acoustic monitoring. The company describes potential applications in brain diseases, including brain tumors and Alzheimer’s, and its platform also includes focused-ultrasound neuromodulation. Structured company information lists $7.01 million in total funding and identifies a Series A as the latest financing type, but provides no financing date or named investors. As a result, the clearest verifiable milestones are the company’s 2022 founding and its reported Series A financing, while the timing and clinical status of individual programs remain unclear.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes Neumous distinct
- 01Uses focused ultrasound and systemically administered microbubbles to enable temporary, localized blood-brain barrier opening without surgery.
- 02Combines neuronavigation with real-time acoustic monitoring to guide and monitor treatment delivery.
- 03Designed to support targeted delivery of a broad range of therapeutic modalities to the brain.
- 04Develops its platform through clinical work and collaborations with pharmaceutical companies, hospitals, academic institutions, and research partners.
Technology & products
- Focused ultrasound platform
A non-invasive therapeutic ultrasound platform designed to temporarily open the blood-brain barrier for targeted delivery of therapeutic agents, with focused-ultrasound neuromodulation also described.
- Focused ultrasound-mediated blood-brain barrier opening platform
- Targeted brain drug delivery using focused ultrasound and microbubbles
- Neuronavigation system for precise ultrasound targeting
- Real-time acoustic monitoring of microbubble activity
- Focused ultrasound neuromodulation
Funding
Investors4
- Aju IB Investment
- KIMCo Foundation
- SL Investment Co., Ltd.
Similar companies
About Neumous
- Products
- Focused ultrasound platform
- Focus areas
- Medical devices, focused ultrasound, blood-brain barrier, drug delivery, neurology, neuroscience, therapeutics, clinical research
- Headquarters
- Seoul, South Korea
- Founded
- 2022
- Employees
- 11–50
- Status
- Active · private